Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Friday.

Several other research firms have also issued reports on APTO. Zacks Investment Research upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Monday, August 14th. HC Wainwright upgraded shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $1.00 to $4.00 in a research note on Thursday, September 7th. Roth Capital reiterated a “buy” rating and issued a $5.00 target price on shares of Aptose Biosciences in a research note on Monday, October 23rd. Finally, Canaccord Genuity set a $7.00 price target on shares of Aptose Biosciences and gave the company a “buy” rating in a research report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $4.50.

Aptose Biosciences (NASDAQ:APTO) traded down $0.02 during midday trading on Friday, hitting $2.01. 312,144 shares of the stock traded hands, compared to its average volume of 380,886. Aptose Biosciences has a 12-month low of $0.78 and a 12-month high of $2.30.

COPYRIGHT VIOLATION WARNING: “Aptose Biosciences (APTO) Downgraded by ValuEngine to Strong Sell” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/03/aptose-biosciences-apto-downgraded-by-valuengine-to-strong-sell.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.